Kitaoka Taisuke, Morimoto Masahito, Hashimoto Toshiaki, Tsuda Yoshimi, Nakatsu Tadanori, Kyotani Shojiro
1Tokushima Bunri University, Graduate School of Pharmaceutical Sciences, Nishihamahouji, Yamashiro-cho, Tokushima-shi, Tokushima, 770-8514 Japan.
Department of pharmacy, Japanese Red Cross Tokushima Hinomine Rehabilitation Center for People with Disabilities, Shinbiraki, Chuden-cho, Komathushima-shi, Tokushima, 773-0014 Japan.
J Pharm Health Care Sci. 2020 Apr 25;6:8. doi: 10.1186/s40780-020-00164-w. eCollection 2020.
Autism spectrum disorder (ASD) is a neurodevelopmental disorder, mainly characterized by impairment of social communication and restricted interests. ASD is frequently accompanied by attention deficit hyperactivity disorder (ADHD), which is characterized by carelessness, hyperactivity and impulsivity (ASD/ADHD). It has been suggested that ASD and ADHD are associated with oxidative stress, that is, that patients with ASD/ADHD are in a state of increased oxidative stress. There are currenr tly no objective or biological test criteria for evaluating the efficacy of drug therapy in these patients. The purpose of this study was to evaluate whether oxidative stress markers [serum reactive oxygen metabolites (d-ROMs) levels and biological antioxidant potential (BAP)] can be used as objective indicators for evaluating the efficacy of drug treatment in ASD/ADHD patients.
The subjects of this study subjects were 50 Japanese patients with ASD/ADHD aged 4 to 14 years old. Serum samples were obtained from the patients to measure the serum levels of d-ROMs and the serum BAP. The study subjects were divided into two age groups: preschool children (4 to 6 years old) and school-age children (7 to 14 years old), and the serum levels of d-ROMs, serum BAP, serum BAP/d-ROMs ratio (hereinafter, the prefix serum will be dropped), and scores on the Parent-interview ASD Rating Scales-Text Revision (PARS-TR) and ADHD Rating Scale (ADHD-RS) were determined before and after drug therapy and compared between the two groups. In addition, changes in the d-ROMs, BAP and BAP/d-ROMs ratio and changes in the scores on the PARS-TR and ADHD-RS after treatment were also analyzed.
Significant decrease of the d-ROMs, BAP, and scores on the PARS-TR and ADHD-RS, with a significant increase of the BAP/d-ROMs ratio, was observed after treatment. In addition, a significant correlation was observed between the changes in the d-ROMs and changes in the scores on the PARS-TR and ADHD-RS after treatment in the school-age ASD/ADHD children.
Our results suggest the possibility that the serum level of d-ROMs may be useful as an objective assessment marker to supplement the subjective assessment of the effects of drug treatment in school-age children with ASD/ADHD.
自闭症谱系障碍（ASD）是一种神经发育障碍，主要特征为社交沟通受损和兴趣受限。ASD常伴有注意力缺陷多动障碍（ADHD），其特征为粗心、多动和冲动（ASD/ADHD）。有人提出，ASD和ADHD与氧化应激有关，即ASD/ADHD患者处于氧化应激增加的状态。目前尚无评估这些患者药物治疗疗效的客观或生物学检测标准。本研究的目的是评估氧化应激标志物[血清活性氧代谢产物（d-ROMs）水平和生物抗氧化能力（BAP）]是否可作为评估ASD/ADHD患者药物治疗疗效的客观指标。
本研究的受试者为50名4至14岁的日本ASD/ADHD患者。采集患者的血清样本，以测量血清d-ROMs水平和血清BAP。研究对象分为两个年龄组：学龄前儿童（4至6岁）和学龄儿童（7至14岁），在药物治疗前后测定血清d-ROMs水平、血清BAP、血清BAP/d-ROMs比值（以下简称血清将省略）以及父母访谈ASD评定量表-文本修订版（PARS-TR）和ADHD评定量表（ADHD-RS）的得分，并在两组之间进行比较。此外，还分析了治疗后d-ROMs、BAP和BAP/d-ROMs比值的变化以及PARS-TR和ADHD-RS得分的变化。
治疗后观察到d-ROMs、BAP以及PARS-TR和ADHD-RS得分显著降低，BAP/d-ROMs比值显著升高。此外，在学龄期ASD/ADHD儿童中，治疗后d-ROMs的变化与PARS-TR和ADHD-RS得分的变化之间存在显著相关性。
我们的结果表明，血清d-ROMs水平有可能作为一种客观评估标志物，以补充对学龄期ASD/ADHD儿童药物治疗效果的主观评估。
